NKCC

NKCC Products

  • All (5)
  • NKCC Inhibitors (5)
  • New NKCC Products
Catalog No. Product Name Information Product Use Citations Product Validations
S8615 DCA (Sodium dichloroacetate) DCA (Sodium dichloroacetate), a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress Na+-K+-2Cl- cotransporter and a mitochondrial potassium-ion channel axis. Sodium dichloroacetate increases reactive oxygen species (ROS) generation, triggers apoptosis in cancer cells, and inhibits tumor growth.
iScience, 2024, 27(1):108645
Cell Death Dis, 2023, 14(7):457
Nat Commun, 2022, 13(1):1417
S1603 Furosemide Furosemide is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used in the treatment of congestive heart failure and edema.
Ren Fail, 2022, 44(1):1345-1355
Environ Toxicol Chem, 2021, 10.1002/etc.5018
Biomed Pharmacother, 2018, 101:145-154
S1287 Bumetanide Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. Bumetanide is a selective Na+-K+-Cl- cotransporter 1 (NKCC1) inhibitor, weakly inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j
S5194 Furosemide sodium Furosemide (Frusemide) sodium is a potent and orally active inhibitor of Na-K-Cl cotransporter (NKCC). Furosemide sodium is a subtype-selective antagonist of gamma-aminobutyric acid type A (GABAA) receptor.
Ren Fail, 2022, 44(1):1345-1355
E2358 Azosemide Azosemide is a potent Na+–K+–2Cl cotransporter NKCC1 inhibitor with IC50s of 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B, respectively.
S8615 DCA (Sodium dichloroacetate) DCA (Sodium dichloroacetate), a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress Na+-K+-2Cl- cotransporter and a mitochondrial potassium-ion channel axis. Sodium dichloroacetate increases reactive oxygen species (ROS) generation, triggers apoptosis in cancer cells, and inhibits tumor growth.
iScience, 2024, 27(1):108645
Cell Death Dis, 2023, 14(7):457
Nat Commun, 2022, 13(1):1417
S1603 Furosemide Furosemide is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used in the treatment of congestive heart failure and edema.
Ren Fail, 2022, 44(1):1345-1355
Environ Toxicol Chem, 2021, 10.1002/etc.5018
Biomed Pharmacother, 2018, 101:145-154
S1287 Bumetanide Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. Bumetanide is a selective Na+-K+-Cl- cotransporter 1 (NKCC1) inhibitor, weakly inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j
S5194 Furosemide sodium Furosemide (Frusemide) sodium is a potent and orally active inhibitor of Na-K-Cl cotransporter (NKCC). Furosemide sodium is a subtype-selective antagonist of gamma-aminobutyric acid type A (GABAA) receptor.
Ren Fail, 2022, 44(1):1345-1355
E2358 Azosemide Azosemide is a potent Na+–K+–2Cl cotransporter NKCC1 inhibitor with IC50s of 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B, respectively.

Choose Selective NKCC Inhibitors

Tags: NKCC inhibitor|NKCC agonist|NKCC activator|NKCC inducer|NKCC antagonist|NKCC signaling pathway|NKCC assay kit